A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR
Condition(s) studied
Study summary
The main purpose is to evaluate the accuracy of myocardial imaging obtained through integrated 18F-FDG PET/MR in detecting viable myocardium. The secondary objective is to evaluate whether myocardial imaging obtained through integrated 18F-FDG PET/MR can replace 18F-FDG PET combined with 99mTc MIBI SPECT/CT gated myocardial perfusion imaging.
Eligibility
Primary outcome measure(s)
- Myocardial perfusion tomographic imaging — After the patient signs the informed consent form and completes the scan, an average of 2 days.
In accordance with the guidelines established by the American Heart Association, the left ventricular myocardium is segmented into 17 distinct regions and subjected to visual assessment for the identification of reversible myocardial perfusion abnormalities or defects. - Myocardiac metabolic Imaging — After the patient signs the informed consent form and completes the scan, an average of 2 days.
In accordance with the guidelines established by the American Heart Association, the left ventricular myocardium is partitioned into 17 segments, which are subsequently assessed for the presence of diminished myocardial FDG uptake.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shanghai East Hospital | Shanghai | Shanghai Municipality | Recruiting |
More Shanghai East Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06712862 on ClinicalTrials.gov ↗ ← All trials in China